ReviewEye (London, England)2024
Corneal neuropathic pain: a review to inform clinical practice.
Review in Eye (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 20 citations in OpenAlex.
- Neuropathic Corneal Pain and Blepharospasm: A Case Series.Diagnostics (Basel, Switzerland) · 2026Article
- In vivo confocal microscopic evaluation of patients with epidermolysis bullosa demonstrates severe loss of corneal nerves.American journal of ophthalmology case reports · 2026Article
- Regenerative Medicine Approaches to Craniofacial and Corneal Neuropathic Pain.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Current and Developing Therapeutics for Dry Eye Disease: Targeting Ion Channels.Current issues in molecular biology · 2026Review
- Emerging Technologies in Corneal Nerve Evaluation for Dry Eye and Ocular Surface Disease: A Review.Journal of clinical medicine · 2026Review
- Corneal Sensitivity with the Non-contact Esthesiometer as Compared to the Cotton Wisp Test in Patients with Ocular Surface Diseases.Ophthalmology and therapy · 2026Article
- Focused Narrative Review: Non-Pharmacological, Noninvasive Neurostimulation or Neuromodulation Treatment of Ocular Neuropathic Pain.Clinical ophthalmology (Auckland, N.Z.) · 2026Review
- International Survey of Current Approaches to the Management of Neuropathic Corneal Pain by Experts.Ophthalmology and therapy · 2025Article
- Dry Eye Disease and Psychiatric Disorders: Neuroimmune Mechanisms and Therapeutic Perspectives.International journal of molecular sciences · 2025Review
- Vitamin abnormalities in neuropathic corneal pain.Eye and vision (London, England) · 2025Review
- Recent Advances in Optoelectronic Synaptic Devices for Neuromorphic Computing.Biomimetics (Basel, Switzerland) · 2025Review
- Long-Term Evolution of Chronic Neuropathic Ocular Pain and Dry Eye Following Corneal Refractive Surgery.Journal of clinical medicine · 2025Article
- Modeling Neuropathic Corneal Pain: Pulled Nerve Approach With Elevated Krt16 Gene Expression.Investigative ophthalmology & visual science · 2025Article
- Neuro-ophthalmology: recent advances and paradigm shifts.Eye (London, England) · 2024Article
- Insights into the quality and guideline consistency of dry eye disease treatment videos on Chinese short-video platforms.Digital healthArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Corneal neuropathic pain (CNP) is a poorly defined disease entity characterised by an aberrant pain response to normally non-painful stimuli and categorised into having peripheral and central mechanisms, with the former responding to instillation of topical anaesthetic. CNP is a challenging condition to diagnose due to numerous aetiologies, an absence of clinical signs and ancillary tests (in vivo confocal microscopy and esthesiometry), lacking the ability to confirm the diagnosis and having limited availability. Symptomatology maybe mirrored by severe and chronic forms of dry eye disease (DED), often leading to misdiagnosis and inadequate treatment. In practice, patients with suspected CNP can be assessed with questionnaires to elicit symptoms. A thorough ocular assessment is also performed to exclude any co-existent ocular conditions. A medical and mental health history should be sought due to associations with autoimmune disease, chronic pain syndromes, anxiety and depression. Management begins with communicating to the patient the nature of their condition. Ophthalmologists can prescribe topical therapies such as autologous serum eyedrops to optimise the ocular surface and promote neural regeneration. However, a multi-disciplinary treatment approach is often required, including mental health support, particularly when there are central mechanisms. General practitioners, pain specialists, neurologists and psychologists may be needed to assist with oral and behavioural therapies. Less data is available to support the safety and efficacy of adjuvant and surgical therapies and the long-term natural history remains to be determined. Hence clinical trials and registry studies are urgently needed to fill these data gaps with the aim to improve patient care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.